Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.30 |
| ▸ | PDE8B | O95263 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170833 | 0.83 | — | — | |
| SCHEMBL31517587 | 0.82 | — | — | |
| SCHEMBL1593290 | 0.80 | KMT2A (0.47) | KMT2APDE8BHRH4 | |
| SCHEMBL234785 | 0.80 | KMT2A (0.44) | KMT2APDE8BHRH4 | |
| Ammonia Solution, Strong SCHEMBL3939167 | 0.78 | KMT2A (0.46) | KMT2APDE8BHRH4 | |
| SCHEMBL16803471 | 0.78 | KMT2A (0.50) | KMT2AHRH4 | |
| SCHEMBL8015569 | 0.78 | KMT2A (0.50) | KMT2AHRH4 | |
| SCHEMBL16664269 | 0.77 | HRH4 (0.51) | KMT2AHRH4 | |
| SCHEMBL25261249 | 0.75 | KMT2A (0.34) | KMT2APDE8BHRH4 | |
| Hydrochloric Acid SCHEMBL16648497 | 0.75 | HRH4 (0.50) | KMT2AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11026946-B2 | Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2021-06-08 | — | — | US | disclosed |
| US-11026946-B2 | Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2021-06-08 | — | — | US | disclosed |
| US-20200129515-A1 | Pharmacologically Active Alicyclic-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | RICHTER GEDEON NYRT. (HU) | 2020-04-30 | — | — | US | disclosed |
| US-20200129515-A1 | Pharmacologically Active Alicyclic-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | RICHTER GEDEON NYRT. (HU) | 2020-04-30 | — | — | US | disclosed |
| CN-110431142-A | Alicyclic substituted pyrazolo [1,5-a] pyrimidine derivatives of pharmacological activity | RICHTER GEDEON NYRT | 2019-11-08 | — | — | CN | disclosed |
| WO-2015087995-A1 | CYCLOALKYL OR HETEROCYCLYL PYRAZOLOPYRIDINE DERIVATIVE | 第一三共株式会社 | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129515-A1 | Pharmacologically Active Alicyclic-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | GABRA5, GABRA1, P2RX5 | GSK3A 1645/4885GSK3B 1834/4885KMT2A 3846/4885 |
| US-11026946-B2 | Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | GABRA5, GABRA1, P2RX5 | GSK3A 1645/4885GSK3B 1834/4885KMT2A 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.